



More Evidence. More Confidence. More Successful Outcomes.

More Evidence.

At LINC and JET Congress 2023, several clinical updates were shared covering our DET portfolio, including **4-year data for the Ranger II SFA RCT and several registries.**

This underscores our commitment to supporting physicians in making decisions driven by clinical evidence.



*These investigator-sponsored studies are supported by grant funding from Boston Scientific. Boston Scientific is not responsible for the collection, analysis or reporting of these studies which remain the sole responsibility of the investigators. Information for the use in countries with applicable product registrations.

**The CAPSICUM study was supported by the Research Association for Lower Limb Artery Revascularization (LIBERAL) sponsored by the following companies: Boston Scientific Japan K.K., OrbisNeich Foundation, Terumo Corp., and Kaneka Medix Corporation. The funding companies played no role in the design of the study, selection of the enrolled patients, treatment strategy, revascularization procedures or equipment, or collection, analysis, or interpretation of the data.

*** No BSC funding


More Confidence

Level-1 evidence from the IMPERIAL RCT is confirmed by Real-World Data of the **MÜNSTER ALL-COMERS REGISTRY at 5 years** showing **consistent performance of Eluvia even in complex lesions.**



More Successful outcomes

Ranger delivers exceptional outcomes backed by durable, long-term results as demonstrated in the **Ranger II SFA RCT 3 and 4-year results.**



1. Brodmann M. Randomised Control Trial Data. The Pinnacle of Proof, LINC 2023, June 6, 2023, Leipzig, Germany
2. Gray W. 5-year Results from the IMPERIAL Randomized Study of Eluvia and Zilver PTX Drug-eluting Stents and Long Lesion Substudy for Femoropopliteal Artery Disease, CRT 2023, Washington DC Feb 27, 2023
3. Torsello G. LINC 2023, June 6, 2023, Leipzig, Germany.
4. Rosentheil K, et al. N Engl J Med. 2015;373(2):145-153. doi:10.1056/NEJMoa1406235.
5. Lyden SP, et al. J Endovasc Ther. 2022;29(6):929-936. doi:10.1177/152666028211068769.
6. Schneider PA, et al. Circ Cardiovasc Interv. 2018;11(1):e005891.

CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings and instructions for use can be found in the product labelling supplied with each device. Products shown for INFORMATION purposes only and may not be approved or for sale in certain countries. This material not intended for use in France. 2023 Copyright © Boston Scientific Corporation or its affiliates. All rights reserved. Results from different clinical investigations are not directly comparable. Information provided for educational purposes only.